Company intelligence / Profile preview

Archimedes Pharma

Reading, Berkshire, United Kingdomleadiq.com ↗

Ownership: Private
Development stage: Other

Overview

Archimedes Pharma developed proprietary nasal and oral drug delivery technologies, with its lead product PecFent (fentanyl pectin nasal spray) approved for breakthrough cancer pain in Europe. The company also advanced programs for chemotherapy-induced nausea and vomiting, with several clinical milestones including successful Phase III data for NasalFent. The company was recognized as SME Pharma Company of the Year by Scrip Awards in 2009.

Therapeutic areas: Oncology
Modalities: Small moleculeNasal spray drug deliveryOral drug delivery
Industry: Biotech

Partnerships

Almac Discovery (development partnership on antiemetic therapy)

Beyond the preview

Go deeper on Archimedes Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Archimedes Pharma.

Explore the full profile